[New options in the treatment of various forms of diabetic neuropathy].
The classification and incidence of diabetic neuropathy, and the therapeutic options available, are presented in the evidence-based guidelines of the German Diabetes Association for sensorimotor and autonomic neuropathy (www. AWMF.de). Treatment decisions relating basic measures (e.g. optimization of management, multifactorial medication), neuropathic pain and diabetic-neuropathic foot syndrome can be taken on the basis of a simple care pathway. More recent therapeutic options in the treatment of pain are gabapentin, pregabalin, duloxetine and other drugs. For the treatment of erectile dysfunction, the new PDE5 inhibitors vardenafil and tadalafil are now available in addition to sildenafil. A new candidate for a pathogenetically valid treatment is the PKC inhibitor ruboxistaurin.
Haslbeck
M
M
Institut für Diabetesforschung, München.
D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects; D001342:Autonomic Nervous System Diseases / Q000175:diagnosis / Q000628:therapy*; D003131:Combined Modality Therapy; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis / Q000628:therapy*; D003929:Diabetic Neuropathies / Q000175:diagnosis / Q000628:therapy*; D019317:Evidence-Based Medicine; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects; D010147:Pain Measurement; D017410:Practice Guidelines as Topic; D020886:Somatosensory Disorders / Q000175:diagnosis / Q000628:therapy*
D000700:Analgesics; D007004:Hypoglycemic Agents; D007328:Insulin
Sensomotorische und autonome Neuropathie. Neue Therapieoptionen, die Sie kennen sollten.